New clinical trial involving a paclitaxel nanoparticle formulation

With the collaboration of Abbott, a Wake Forest University scientist is conducting a clinical trial to study the best dose and best way to give paricalcitol and to see how well it works when given together with chemotherapy in treating patients with metastatic breast cancer. It is now registered in the ClinicalTrials.gov database under reference NCT01055288. According to this page : “Beginning on day 1, patients receive oral paricalcitol. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation, docetaxel, or paclitaxel once a week or ixabepilone once every 3 weeks. Treatment continues for at least 12 weeks in the absence of disease progression or unacceptable toxicity“

Advertisements